ERBB2 and breast cancer: We demonstrated that well-trained deep learning models based on ResNet (Supplementary Fig. S3 and Method S5) can differentiate EGFR trajectories from six breast cancer cell lines (Fig. 2) and from three groups of cells with distinct receptor status (HR+, HER2+ and TN, Fig. 3) with high accuracies (83% and 85%, respectively).